Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19Essy Mozaffari, André C. Kalil, Aastha Chandak et al.|Clinical Infectious Diseases|2024Cited by 15
Racial and Ethnic Disparities in COVID-19 Treatments in the United StatesEssy Mozaffari, Chidinma Chima-Melton, Aastha Chandak et al.|Journal of Racial and Ethnic Health Disparities|2024Cited by 7
Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized PatientsEssy Mozaffari, Alpesh Amin, Aastha Chandak et al.|Clinical Therapeutics|2024Cited by 6
Late Breaking Abstract - Remdesivir reduces progression to ICU in patients hospitalized with COVID-19Rikisha Gupta, Anand P. Chokkalingam, Valentina Shvachko et al.|Unknown|2023Cited by 0
Corrigendum to: “Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients” [Clin Ther 2024;46:778–784]Essy Mozaffari, Alpesh Amin, Aastha Chandak et al.|Clinical Therapeutics|2024Cited by 0